Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$72.91 USD

72.91
14,177,332

+3.92 (5.68%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $73.06 +0.15 (0.21%) 7:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised

by Zacks Equity Research

Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.

AHCO vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

AHCO vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 9.80% and 4.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for These 4 Medical Products Stocks in Q1 Earnings?

by Zacks Equity Research

Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.

Unveiling Boston Scientific (BSX) Q1 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.

Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable

by Zacks Equity Research

Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.

Boston Scientific (BSX) Faces Rising Costs, Competition

by Zacks Equity Research

With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.

AHCO or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AHCO vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) and Scivita Medical Expand Partnership

by Zacks Equity Research

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Abbott (ABT) Expands in Canada With First Eterna SCS Use

by Zacks Equity Research

Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.

AHCO vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

AHCO vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail

by Zacks Equity Research

Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.

Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

by Zacks Equity Research

Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Envista (NVST) Down 5.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Boston Scientific (BSX) Grows IC Business With New FDA Nod

by Zacks Equity Research

The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.

Why Is Boston Scientific (BSX) Up 2.1% Since Last Earnings Report?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Shaun Pruitt headshot

C3.ai's (AI) Stock Is Soaring After Earnings But is it Time to Buy?

by Shaun Pruitt

As one of the more promising artificial intelligence companies, let's see if it's time to buy C3.ai's (AI) stock after revenue and contract growth fuel its post-earnings rally.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Boston Scientific Corporation (BSX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?

by Zacks Equity Research

Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.